CD13 as a new tumor target for antibody-drug conjugates: validation with the conjugate MI130110
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1756-8722
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
CD13 as a new tumor target for antibody-drug conjugates: validation with the conjugate MI130110 ; volume:13 ; number:1 ; day:7 ; month:4 ; year:2020 ; pages:1-15 ; date:12.2020
Journal of hematology & oncology ; 13, Heft 1 (7.4.2020), 1-15, 12.2020
- Urheber
-
Domínguez, Juan Manuel
Pérez-Chacón, Gema
Guillén, María José
Muñoz-Alonso, María José
Somovilla-Crespo, Beatriz
Cibrián, Danay
Acosta-Iborra, Bárbara
Adrados, Magdalena
Muñoz-Calleja, Cecilia
Cuevas, Carmen
Sánchez-Madrid, Francisco
Avilés, Pablo
Zapata, Juan M.
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s13045-020-00865-7
- URN
-
urn:nbn:de:101:1-2020062321474681319826
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:58 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Domínguez, Juan Manuel
- Pérez-Chacón, Gema
- Guillén, María José
- Muñoz-Alonso, María José
- Somovilla-Crespo, Beatriz
- Cibrián, Danay
- Acosta-Iborra, Bárbara
- Adrados, Magdalena
- Muñoz-Calleja, Cecilia
- Cuevas, Carmen
- Sánchez-Madrid, Francisco
- Avilés, Pablo
- Zapata, Juan M.
- SpringerLink (Online service)
Ähnliche Objekte (12)
Antibody–drug conjugates in ovarian cancer
Antibody–drug conjugates—the magic bullet?
Antibody–drug conjugates in solid tumors: a look into novel targets
Co-administered antibody improves penetration of antibody–dye conjugate into human cancers with implications for antibody–drug conjugates
The First FDA-Approved Antibody-Drug Conjugate
Fate of Antibody-Drug Conjugates in Cancer Cells
Antibody–drug conjugates (ADCs) in lung cancer treatment
Ethynylphosphonamidates in the Synthesis of Antibody–Drug Conjugates
Fcγ Receptor-Dependent Internalization and Off-Target Cytotoxicity of Antibody-Drug Conjugate Aggregates
Safety and Tolerability of Antibody-Drug Conjugates in Cancer
Potential of antibody–drug conjugates (ADCs) for cancer therapy
Antibody–drug conjugates in the treatment of lymphoid neoplasms
Antibody–drug conjugates in ovarian cancer
Antibody–drug conjugates—the magic bullet?
Antibody–drug conjugates in solid tumors: a look into novel targets
Co-administered antibody improves penetration of antibody–dye conjugate into human cancers with implications for antibody–drug conjugates
The First FDA-Approved Antibody-Drug Conjugate
Fate of Antibody-Drug Conjugates in Cancer Cells
Antibody–drug conjugates (ADCs) in lung cancer treatment
Ethynylphosphonamidates in the Synthesis of Antibody–Drug Conjugates
Fcγ Receptor-Dependent Internalization and Off-Target Cytotoxicity of Antibody-Drug Conjugate Aggregates
Safety and Tolerability of Antibody-Drug Conjugates in Cancer
Potential of antibody–drug conjugates (ADCs) for cancer therapy
Antibody–drug conjugates in the treatment of lymphoid neoplasms
Antibody–drug conjugates in ovarian cancer
Antibody–drug conjugates—the magic bullet?
Antibody–drug conjugates in solid tumors: a look into novel targets
Co-administered antibody improves penetration of antibody–dye conjugate into human cancers with implications for antibody–drug conjugates
The First FDA-Approved Antibody-Drug Conjugate
Fate of Antibody-Drug Conjugates in Cancer Cells
Antibody–drug conjugates (ADCs) in lung cancer treatment
Ethynylphosphonamidates in the Synthesis of Antibody–Drug Conjugates
Fcγ Receptor-Dependent Internalization and Off-Target Cytotoxicity of Antibody-Drug Conjugate Aggregates
Safety and Tolerability of Antibody-Drug Conjugates in Cancer
Potential of antibody–drug conjugates (ADCs) for cancer therapy